Recent studies in mice revealed that some stem cells do not replenish all blood cell lineages. Researchers from the ...
Every second, millions of blood cells are produced in the human body, and about 90% of the cells replaced daily are blood ...
Thepatent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients ...
The Sickle Cell Disease Treatment Market offers significant opportunities with advancements in gene editing, stem cell ...
The market is driven by advancements in gene therapy, stem cell-based treatments, and increasing investment in rare diseases. Despite high costs, the market for these innovative treatments is growing, ...
Rocket Pharmaceuticals advances gene therapies for rare diseases. Momentum aligns with broader biotech trends in the Nasdaq ...
Stem cell transplant options have expanded, utilizing matched siblings, unrelated donors, and umbilical cord blood, enhancing access for hematologic cancer patients. October brought developments in ...
Key drivers of this growth include the rising incidence of degenerative bone diseases, diabetic ulcers, traumatic injuries, sports-related ...
On November 7, Jiahui International Cancer Center (JICC) successfully treated a 78-year-old patient from New Zealand with ...
Damora Therapeutics, the sixth company launched based on assets developed by Paragon Therapeutics, is advancing a portfolio of anti-mutant calreticulin (mutCALR) targeted therapies, led by DMR-001, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback